NO20021932L - Medikament egnet til behandling av ondartede tumorer - Google Patents

Medikament egnet til behandling av ondartede tumorer

Info

Publication number: NO20021932L
Authority: NO; Norway
Prior art keywords: treatment; malignant tumors; medication suitable; compounds; medication
Prior art date: 1999-10-25

Application number

NO20021932A

Other languages

English (en)

Other versions

NO323320B1 (no

NO20021932D0 (no

Inventor

Gunnar Hedlund

Karl Jansson

Stig Joensson

Anders Bjoerk

Original Assignee

Active Biotech Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-25

Filing date

2002-04-24

Publication date

2002-06-21

1999-10-25 Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx

2002-04-24 Application filed by Active Biotech Ab filed Critical Active Biotech Ab

2002-04-24 Publication of NO20021932D0 publication Critical patent/NO20021932D0/no

2002-06-21 Publication of NO20021932L publication Critical patent/NO20021932L/no

2007-03-12 Publication of NO323320B1 publication Critical patent/NO323320B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20021932A 1999-10-25 2002-04-24 Medikament egnet til behandling av ondartede tumorer NO323320B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US16140799P	1999-10-25	1999-10-25
SE9903838A SE9903838D0 (sv)	1999-10-25	1999-10-25	Novel compounds
US21281600P	2000-06-21	2000-06-21
SE0002320A SE0002320D0 (sv)	1999-10-25	2000-06-21	Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en)	1999-10-25	2000-10-24	Drugs for the treatment of malignant tumours

Publications (3)

Publication Number	Publication Date
NO20021932D0 NO20021932D0 (no)	2002-04-24
NO20021932L true NO20021932L (no)	2002-06-21
NO323320B1 NO323320B1 (no)	2007-03-12

Family

ID=27484521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021932A NO323320B1 (no)	1999-10-25	2002-04-24	Medikament egnet til behandling av ondartede tumorer

Country Status (21)

Country	Link
EP (1)	EP1224172B1 (no)
JP (1)	JP3950337B2 (no)
KR (2)	KR100674160B1 (no)
AT (1)	ATE358668T1 (no)
AU (1)	AU775057B2 (no)
CA (1)	CA2386775C (no)
CZ (1)	CZ298534B6 (no)
DE (1)	DE60034240T2 (no)
DK (1)	DK1224172T3 (no)
EE (1)	EE200200207A (no)
ES (1)	ES2280258T3 (no)
HK (1)	HK1049830A1 (no)
HR (1)	HRP20020353A2 (no)
HU (1)	HU229072B1 (no)
IL (2)	IL148782A0 (no)
IS (1)	IS2750B (no)
NO (1)	NO323320B1 (no)
NZ (1)	NZ518296A (no)
SE (1)	SE0002320D0 (no)
UA (1)	UA73748C2 (no)
WO (1)	WO2001030758A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8314124B2 (en)	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) *	2004-02-06	2004-02-06	Active Biotech Ab	New composition containing quinoline compounds
SE0401578D0 (sv) *	2004-06-18	2004-06-18	Active Biotech Ab	Novel compounds
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
RS56873B1 (sr)	2004-06-24	2018-04-30	Vertex Pharma	Modulatori atp-vezujućih kasetnih transportera
WO2007047863A2 (en) *	2005-10-19	2007-04-26	Teva Pharmaceutical Industries, Ltd.	Crystals of laquinimod sodium, and process for the manufacture thereof
EP3219705B1 (en)	2005-12-28	2020-03-11	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2007258366B2 (en)	2006-06-12	2012-10-25	Active Biotech, Ab	Stable laquinimod preparations
KR100916160B1 (ko) *	2007-02-21	2009-09-08	(주)바이오버드	약제학적 항암 조성물
EP2065380A1 (en) *	2007-08-22	2009-06-03	F.Hoffmann-La Roche Ag	Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
DK2234485T3 (da)	2007-12-20	2014-02-10	Teva Pharma	Stabile laquinimod-præparater
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
UA104005C2 (ru)	2008-09-03	2013-12-25	Тева Фармасьютикл Индастриз, Лтд.	2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
PT2408750E (pt)	2009-03-20	2015-10-15	Vertex Pharma	Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística
CN103153959A (zh)	2010-10-14	2013-06-12	伊姆纳尔公司	作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类
US8802700B2 (en)	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) *	2011-06-22	2012-12-26	Active Biotech AB	Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EP2819670A1 (en)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
KR20150091077A (ko) *	2012-11-07	2015-08-07	테바 파마슈티컬 인더스트리즈 리미티드	라퀴니모드의 아민염
EP2970129A2 (en)	2013-03-14	2016-01-20	Teva Pharmaceutical Industries Ltd.	Crystals of laquinimod sodium and improved process for the manufacture thereof
CN107108510B (zh) *	2014-09-23	2020-10-23	活跃生物技术有限公司	用于治疗多发性骨髓瘤的喹啉甲酰胺
US9701639B2 (en)	2014-10-07	2017-07-11	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3180005B1 (en)	2014-11-19	2017-12-27	Active Biotech AB	Quinoline carboxamides for use in the treatment of leukemia
WO2019074116A1 (ja)	2017-10-13	2019-04-18	小野薬品工業株式会社	Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CA3163105A1 (en) *	2019-11-28	2021-06-03	Bayer Aktiengesellschaft	Substituted aminoquinolones as dgkalpha inhibitors for immune activation
KR20220149579A (ko)	2020-03-03	2022-11-08	액티브 바이오테크 에이비	조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
EP4153576A4 (en) *	2020-05-21	2024-06-19	StemSynergy Therapeutics, Inc.	NOTCH INHIBITORS AND THEIR USES
MX2023008016A (es)	2021-01-18	2023-07-13	Active Biotech Ab	Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
PL4346773T3 (pl)	2021-05-25	2025-11-03	Active Biotech Ab	Duża liczba cząstek taskwinimodu i ich zastosowanie
JP2024524158A (ja)	2021-07-02	2024-07-05	アクティブバイオテックエイビー	タスキニモドを含有する医薬製品および前記製品の純度を評価する方法
TWI838849B (zh)	2021-09-13	2024-04-11	美商美國禮來大藥廠	Ahr促效劑
AR126963A1 (es)	2021-09-13	2023-12-06	Lilly Co Eli	Agonistas de ahr
EP4452946A4 (en) *	2021-12-20	2025-11-26	Univ Johns Hopkins	CONNECTIONS FOR THE TREATMENT OF CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE52670B1 (en) *	1981-03-03	1988-01-20	Leo Ab	Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) *	1991-04-22	1991-06-05	Fujisawa Pharmaceutical Co	Quinoline derivatives
GB9404378D0 (en) *	1994-03-07	1994-04-20	Fujisawa Pharmaceutical Co	Quinoline derivatives
GB2290786A (en) *	1994-06-30	1996-01-10	Fujisawa Pharmaceutical Co	Quinoline derivatives
SE9801474D0 (sv) *	1998-04-27	1998-04-27	Active Biotech Ab	Quinoline Derivatives
SE9802550D0 (sv) *	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives
SE9802549D0 (sv) *	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives
US6121287A (en) *	1998-07-15	2000-09-19	Active Biotech Ab	Quinoline derivatives

2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active Expired - Fee Related
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active Expired - Fee Related
- 2000-10-24 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en not_active Ceased
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 EP EP00973329A patent/EP1224172B1/en not_active Expired - Lifetime
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR20060054496A (ko)	2006-05-22
IS2750B (is)	2011-08-15
AU1185101A (en)	2001-05-08
DK1224172T3 (da)	2007-08-13
UA73748C2 (en)	2005-09-15
IL148782A (en)	2007-05-15
AU775057B2 (en)	2004-07-15
CA2386775C (en)	2004-07-13
CZ298534B6 (cs)	2007-10-31
KR20020043646A (ko)	2002-06-10
HU229072B1 (en)	2013-07-29
ATE358668T1 (de)	2007-04-15
NO323320B1 (no)	2007-03-12
SE0002320D0 (sv)	2000-06-21
WO2001030758A1 (en)	2001-05-03
KR100674160B1 (ko)	2007-01-24
HUP0203238A3 (en)	2003-05-28
NO20021932D0 (no)	2002-04-24
ES2280258T3 (es)	2007-09-16
IS6329A (is)	2002-04-02
CA2386775A1 (en)	2001-05-03
DE60034240T2 (de)	2007-12-20
CZ20021293A3 (cs)	2002-07-17
EE200200207A (et)	2003-06-16
JP2003512454A (ja)	2003-04-02
DE60034240D1 (de)	2007-05-16
EP1224172A1 (en)	2002-07-24
HK1049830A1 (zh)	2003-05-30
IL148782A0 (en)	2002-09-12
NZ518296A (en)	2003-06-30
HUP0203238A2 (hu)	2003-01-28
HRP20020353A2 (en)	2005-10-31
JP3950337B2 (ja)	2007-08-01
EP1224172B1 (en)	2007-04-04
KR100597938B1 (ko)	2006-07-06

Publication	Publication Date	Title
NO20021932D0 (no)	2002-04-24	Medikament egnet til behandling av ondartede tumorer
YU23202A (sh)	2004-11-25	Lekovi za tretman malignih tumora
DK1519724T3 (da)	2010-01-04	Fredericamycin-derivater som lægemidler til behandling af tumorer
DE60030741D1 (de)	2006-10-26	Chinazoline verbindungen als heilmittel
BR0209431A (pt)	2004-08-03	Novos compostos de 4-anilinoquinolino-3-carboxamidas
BR0112589A (pt)	2003-05-20	Derivados de heteroarila e sua aplicação como medicamento
SE9904505D0 (sv)	1999-12-09	Novel compounds
RU2011138835A (ru)	2013-03-27	Применение производного рапамицина
BR0309355A (pt)	2005-02-22	2-(2,6-diclorofenil)-diarilimidazóis
PL367682A1 (en)	2005-03-07	Dolastatin 10 derivatives
MXPA04001500A (es)	2004-05-14	Compuestos que tienen un efecto sobre la glucocinasa.
DE60206911D1 (de)	2005-12-01	Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE233754T1 (de)	2003-03-15	Diphenyl-piperidin derivate
DE60301339D1 (de)	2005-09-22	Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
MY136267A (en)	2008-09-30	Lipid lowering biphenylcarboxamides
BR0112807A (pt)	2003-07-01	Derivados de indol e sua aplicação como medicamento
MXPA04005809A (es)	2004-09-13	Inhibidores de proteinas quinasas.
ATE339202T1 (de)	2006-10-15	Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
AU2001246999A1 (en)	2001-10-23	New neurokinin antagonists for use as medicaments
SE0400708D0 (sv)	2004-03-22	New compounds and use thereof
NO20030420L (no)	2003-01-27	Medikament for immunoterapi av maligne tumorer
CY1106576T1 (el)	2012-01-25	Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
SE0004827D0 (sv)	2000-12-22	Therapeutic compounds
WO2002098399A3 (en)	2003-02-27	Cancer treatment method and compositions comprising compounds of the ginger family
TW200505913A (en)	2005-02-16	Novel oxazole derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date	Code	Title	Description
2019-05-27	MM1K	Lapsed by not paying the annual fees